Rudrakshi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 20-12-2024
- Paid Up Capital ₹ 0.53 M
as on 20-12-2024
- Company Age 6 Year, 3 Days
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2021)
- Profit 30.04%
(FY 2021)
- Ebitda 25.54%
(FY 2021)
- Net Worth -36.76%
(FY 2021)
- Total Assets 0.24%
(FY 2021)
About Rudrakshi Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.53 M, as per Ministry of Corporate Affairs (MCA) records.
Gopal Biradar and Vidhyavati Gopal serve as directors at the Company.
- CIN/LLPIN
U24111TG2019PTC129451
- Company No.
129451
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jan 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rudrakshi Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vidhyavati Gopal  | Managing Director | 03-Jan-2019 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gopal Biradar | Director | 03-Jan-2019 | Current |
Financial Performance of Rudrakshi Pharmaceuticals.
Rudrakshi Pharmaceuticals Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 30.04% increase in profit. The company's net worth observed a substantial decline by a decrease of 36.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rudrakshi Pharmaceuticals?
In 2021, Rudrakshi Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Rudrakshi Life Sciences LlpActive 5 years 10 months
Gopal Biradar and Vidhyavati Gopal are mutual person
- Rudrakshi Constructions LlpActive 5 years 10 months
Gopal Biradar and Vidhyavati Gopal are mutual person
- Rudrakshi Automotives LlpActive 5 years 9 months
Gopal Biradar and Vidhyavati Gopal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rudrakshi Pharmaceuticals?
Unlock and access historical data on people associated with Rudrakshi Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rudrakshi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rudrakshi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
